# Merck on Thursday reported first-quarter results that topped estimates on strong demand for its cancer immunotherapy Keytruda and some newer products.

*business · news · 2026-04-30 · CNBC*

## Key points

- Merck narrowed its 2026 revenue guidance to $65.8-$67 billion, raising the lower end by $0.3 billion.
- A $3.62 per share acquisition charge from Cidara Therapeutics led to Merck's quarterly net loss.
- New injectable Keytruda formulation achieved $128 million in sales, aiding future post-patent strategy.
- Winrevair sales rose 88% to $525 million, significantly surpassing analyst estimates due to market expansion.
- Gardasil vaccine sales fell 19% amid halted China shipments and lower demand in Japan and the U.S.

**Companies:** Merck
**Countries:** United States, China, Japan

[Read the full story on CNBC](https://www.cnbc.com/2026/04/30/merck-mrk-earnings-q1-2026.html)

---

Canonical: https://newsio.io/n/96c0f5fd-bccb-4a3d-bd84-1d087b31b002/merck-on-thursday-reported-first-quarter-results-that-topped-estimates-on-strong
Summarized by Newsio from CNBC. https://newsio.io/how-it-works